Protagonist Therapeutics PTGX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Protagonist Therapeutics (PTGX) Business Model and Operations Summary
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Key Insights
Protagonist Therapeutics (PTGX) Core Market Data and Business Metrics
Latest Closing Price
$46.88Market Cap
$2.88 BillionPrice-Earnings Ratio
17.11Total Outstanding Shares
61.38 Million SharesTotal Employees
126Dividend
No dividendIPO Date
August 11, 2016SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
7707 Gateway Blvd., Suite 140, Newark, CA, 94560-1160
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-352.05 Million |
| Net Cash Flow | $-99.41 Million |
| Net Cash Flow From Financing Activities, Continuing | $22.35 Million |
| Net Cash Flow From Investing Activities | $-352.05 Million |
| Net Cash Flow From Financing Activities | $22.35 Million |
| Net Cash Flow, Continuing | $-99.41 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Income/Loss | $149.11 Million |
| Basic Earnings Per Share | $2.89 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Other Operating Expenses | $42.56 Million |
| Diluted Average Shares | $187.89 Million |
| Net Income/Loss Attributable To Parent | $170.85 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $1.51 Million |
| Other Comprehensive Income/Loss | $-62.32 Million |
| Comprehensive Income/Loss Attributable To Parent | $172.35 Million |
| Comprehensive Income/Loss | $172.35 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $3.05 Million |
| Current Liabilities | $44.58 Million |
| Noncurrent Liabilities | $27.36 Million |
| Assets | $603.86 Million |
| Noncurrent Assets | $127.09 Million |
| Equity | $531.91 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||